The Patent Finder
US

Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof

US 10,363,216 In force
OverviewFamilyAssignmentsSources & methods
Collateral for a security interest recorded Dec 28, 2023 (SWK Funding LLC).

Term ends Apr 28, 2030 · Medium confidence

Why Medium: A parent in the chain could not be resolved.

Filed Dec 31, 2018 as application 16/236,704 · Granted Jul 30, 2019
Base term, 20 years from filing
Today
20 years from filing
2010 2030
Clock starts
Apr 28, 2010
Term ends
Apr 28, 2030
Granted
Jul 30, 2019
base term fee events Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,213,384, US 9,884,017, to Apr 28, 2030. The term already ends on or before that date, so the cap shortened nothing.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Apr 28, 2010, when application PCT/IB2010/001126, the earliest non-provisional in its chain, was filed (this one was filed Dec 31, 2018); a parent in its chain could not be resolved (the next row)Apr 28, 2030High confidence
Continuity chainA parent in the chain could not be resolveddated from this application's own claimMedium confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 10,213,384, US 9,884,017)resolves to Apr 28, 2030, no earlier than this term, so no changeHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events1 of 2 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderApr 28, 2030Medium confidence

Partial family

Application PCT/IB2010/001126PCT application
no patent term
no patent term
Application 13/263,201No file history here
not computed
not computed
US 9,884,017In force
Apr 2030
Apr 2030
US 10,213,384Lapsed on the fee record
Feb 2023
Feb 2023
US 10,363,216this patent
Apr 2030
Apr 2030
US 10,588,858In force
Apr 2030
Apr 2030
Application 16/779,884Abandoned
not computed
not computed
Partial: 2 of the 7 have no file history here, so a row comes from the patent's own record or names the application alone. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jun 17, 2019
Reel 49492, frame 563
Tamarkin, Dov; Schuz, David; Berman, Tal; Hazot, YohanFoamix Ltd.Assignment of Assignor's Interest
Jul 30, 2019
Reel 49912, frame 45
Foamix Pharmaceuticals Ltd.Perceptive Credit Holdings II, LPPatent Security Agreement
Sep 17, 2019
Reel 50404, frame 114
Foamix Ltd.Foamix Pharmaceuticals, Ltd.Change of Name
Nov 4, 2020
Reel 54306, frame 387
Foamix Pharmaceuticals Ltd.Vyne Pharmaceuticals Ltd.Change of Name
Feb 4, 2021
Reel 55215, frame 298
Vyne Pharmaceuticals Ltd.Vyne Therapeutics Inc.Assignment of Assignor's Interest
Feb 17, 2021
Reel 55326, frame 9
Vyne Therapeutics Inc.Perceptive Credit Holdings II, LPPatent Security Agreement
Sep 20, 2021
Reel 57544, frame 138
Perceptive Credit Holdings II, LPVyne Pharmaceuticals Ltd. (F/K/A Foamix Pharmaceuticals Ltd.)Release of Security Interest
Sep 20, 2021
Reel 57544, frame 708
Perceptive Credit Holdings II, LPVyne Therapeutics Inc. (F/K/A Menlo Therapeutics Inc. and Successor-in-Interest to Vyne Pharmaceuticals Ltd., F/K/A Foamix Pharmaceuticals Ltd.)Release of Security Interest
Dec 22, 2021
Reel 58463, frame 167
Vyne Therapeutics Inc.Vyne Pharmaceuticals Inc.Assignment of Assignor's Interest
Feb 1, 2022
Reel 58925, frame 568
Vyne Therapeutics Inc.; Vyne Pharmaceuticals Inc.Journey Medical CorporationAssignment of Assignor's Interest
Dec 28, 2023
Reel 66157, frame 79
Journey Medical Corporation; JG Pharma, Inc.SWK Funding LLCSecurity Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited